Add this topic to your myFT Digest for news straight to your inbox
Baseimmune aims to predict future pathogen mutations to create jabs that will be effective for longer
Infections quadruple from last year after warnings that warming temperatures will increase cases
Virginia-based drugmaker says switch would attract more US investors
Head of Cancer Research UK calls for more investment and points to heavy reliance on philanthropic funding
Discovery boosts efforts to develop ‘biomarkers’ for debilitating condition and enable treatments
German conglomerate is still struggling with the costly fallout of its $63bn acquisition of Monsanto
Best-selling Tagrisso drug slows progression of most common form of the disease at an early stage
New molecule proves effective in animals against several drug-resistant bacteria
Large study further boosts fast-evolving efforts to predict and prevent neurogenerative diseases
Drug developers raised $6bn in January, helped by a rebound in merger activity
The coffers of Novo Nordisk’s controlling shareholder have been boosted by diabetes and weight loss drugs
Boston and Geneva-based enterprise believes new technology will transform dermatology
Sovereign wealth funds Temasek and Mubadala in talks to fund biotech groups harnessing mind-altering substances
Annual earnings at Anglo-Swedish pharma group miss expectations but revenues rise to $45.8bn
US group relies on some of the sites being purchased by competitor to produce its own treatments
Cancer, diabetes and heart disease patients among those facing chronic shortage of treatments
Pharma companies, while talking up pipelines, are turning to deals to boost their growth outlook
Danish drugmaker to acquire three manufacturing sites as its controlling shareholder buys US company Catalent
Chief executive says customers very willing to pay for Wegovy from their own pockets
Start-ups say new technology could help end animal testing by pharma companies
Investing in new oncology drugs without building up an effective arsenal against infections is a false economy
US reforms will put Big Pharma under pressure but innovative companies will retain their pricing power
Huge reduction in bouts of angioedema increases prospect that technique can combat a range of diseases
James Muir was discriminated against on the basis of his mental health disability
Danish drugmaker reports better than expected earnings for 2023
UK Edition
